Figure 2
From: Impacts of Intralipid on Nanodrug Abraxane Therapy and on the Innate Immune System
In-vitro treatment with Intralipid promotes the polarization of macrophages to an M1-like phenotype. After chemical induction, well-differentiated M0/M1/M2 macrophages were treated with the indicated concentrations of Intralipid (0, 0.02, 0.2 mg/ml) for 72 hrs. Total RNAs were harvested and analyzed by Q-PCR with specific primers against M1 (CD80 and CD215) and M2 (CD206 and CD163) macrophage markers. The expression levels of IPO8 served as internal controls. Data are presented as the mean ± SD of six independent experiments. Results are expressed as how many fold (log2) the expression markers increased or decreased relative to the baseline. The values summarized in the chart denote the relative expression levels in each subtype of macrophage with and without Intralipid treatment. One-way ANOVA was used to evaluate the significance of the difference between the indicated data sets. **p < 0.01; *p < 0.05; ns, not significant.
